Early trial tests re-engineered immune cells to fight tough ovarian cancer
NCT ID NCT04670068
Summary
This early-phase study is testing the safety of a new cell therapy for women with recurrent ovarian cancer that hasn't responded to standard treatments. Doctors modify a patient's own immune cells to recognize and attack cancer cells, then infuse them back into the abdomen. The main goal is to find a safe dose and understand side effects before testing whether it effectively controls the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.